688176 亚虹医药-U
已收盘 09-21 15:00:00
资讯
新帖
简况
每周股票复盘：亚虹医药（688176）将参加科创板业绩说明会
证券之星 · 09-13
每周股票复盘：亚虹医药（688176）将参加科创板业绩说明会
亚虹医药（688176）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月9日股价下跌3.82%
证券之星 · 09-09
亚虹医药（688176）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月9日股价下跌3.82%
亚虹医药（688176）披露2026年半年度报告，8月31日股价下跌0.17%
证券之星 · 08-31
亚虹医药（688176）披露2026年半年度报告，8月31日股价下跌0.17%
亚虹医药（688176）2026年中报简析：增收不增利
证券之星 · 08-30
亚虹医药（688176）2026年中报简析：增收不增利
每周股票复盘：亚虹医药（688176）Q2收入增21.89%
证券之星 · 08-30
每周股票复盘：亚虹医药（688176）Q2收入增21.89%
亚虹医药（688176）披露APLD-2304获得欧盟CE认证，8月28日股价下跌0.5%
证券之星 · 08-28
亚虹医药（688176）披露APLD-2304获得欧盟CE认证，8月28日股价下跌0.5%
亚虹医药：APLD-2304获欧盟CE认证
智通财经 · 08-27
亚虹医药：APLD-2304获欧盟CE认证
每周股票复盘：亚虹医药（688176）APL-2501获FDA临床试验批准
证券之星 · 08-16
每周股票复盘：亚虹医药（688176）APL-2501获FDA临床试验批准
亚虹医药（688176）披露APL-2501临床试验申请获得FDA批准，8月13日股价上涨3.29%
证券之星 · 08-13
亚虹医药（688176）披露APL-2501临床试验申请获得FDA批准，8月13日股价上涨3.29%
每周股票复盘：亚虹医药（688176）就Photocure仲裁案提起反请求
证券之星 · 08-09
每周股票复盘：亚虹医药（688176）就Photocure仲裁案提起反请求
亚虹医药（688176）披露关于仲裁进展暨提起仲裁反请求的公告，8月5日股价上涨6.8%
证券之星 · 08-05
亚虹医药（688176）披露关于仲裁进展暨提起仲裁反请求的公告，8月5日股价上涨6.8%
每周股票复盘：亚虹医药（688176）收仲裁通知涉440万美元
证券之星 · 07-26
每周股票复盘：亚虹医药（688176）收仲裁通知涉440万美元
亚虹医药（688176）披露关于收到仲裁通知的公告，7月23日股价上涨1.14%
证券之星 · 07-23
亚虹医药（688176）披露关于收到仲裁通知的公告，7月23日股价上涨1.14%
亚虹医药（688176）1.35亿股限售股将于7月1日解禁，占总股本23.68%
证券之星 · 07-01
亚虹医药（688176）1.35亿股限售股将于7月1日解禁，占总股本23.68%
每周股票复盘：亚虹医药（688176）23.68%限售股将上市流通
证券之星 · 06-28
每周股票复盘：亚虹医药（688176）23.68%限售股将上市流通
亚虹医药（688176）披露首次公开发行部分限售股上市流通公告，6月23日股价上涨0.5%
证券之星 · 06-23
亚虹医药（688176）披露首次公开发行部分限售股上市流通公告，6月23日股价上涨0.5%
每周股票复盘：亚虹医药（688176）两期股权激励完成归属
证券之星 · 06-20
每周股票复盘：亚虹医药（688176）两期股权激励完成归属
亚虹医药（688176）披露核心技术人员调整公告，6月17日股价下跌2.22%
证券之星 · 06-17
亚虹医药（688176）披露核心技术人员调整公告，6月17日股价下跌2.22%
亚虹医药（688176）披露2024年限制性股票激励计划第一个归属期归属结果公告，6月16日股价上涨1.57%
证券之星 · 06-16
亚虹医药（688176）披露2024年限制性股票激励计划第一个归属期归属结果公告，6月16日股价上涨1.57%
每周股票复盘：亚虹医药（688176）2025年股东会通过利润分配等议案
证券之星 · 05-31
每周股票复盘：亚虹医药（688176）2025年股东会通过利润分配等议案
暂无数据
公司概况
公司名称：
江苏亚虹医药科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-07
主营业务：
江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域，提供涵盖诊断、治疗、随访等诊疗一体化解决方案。公司的主要产品是APL-1702(希维她)、APL-2302、APL-2501、AT-021、APL-1706(海克威)、APLD-2304、APL-2401、APL-024、APL-1202、APL-1401、APL-2301。
发行价格：
22.98
{"stockData":{"symbol":"688176","market":"SH","secType":"STK","nameCN":"亚虹医药-U","latestPrice":14.73,"timestamp":1789974000000,"preClose":12.7,"halted":0,"volume":36559541,"delay":0,"changeRate":0.1598,"floatShares":572000000,"shares":572000000,"eps":-0.8612,"marketStatus":"已收盘","change":2.03,"latestTime":"09-21 15:00:00","open":12.85,"high":14.84,"low":12.85,"amount":519000000,"amplitude":0.1567,"askPrice":14.73,"askSize":91,"bidPrice":14.72,"bidSize":40,"shortable":0,"etf":0,"ttmEps":-0.8612,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790040600000},"marketStatusCode":5,"adr":0,"adjPreClose":12.7,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789954200000,1789961400000],[1789966800000,1789974000000]],"highLimit":13.97,"lowLimit":11.43,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":572192168,"isCdr":false,"pbRate":6.23,"roa":"--","roe":"--","epsLYR":-0.74,"committee":-0.568462,"marketValue":8428000000,"turnoverRate":0.0639,"status":0,"afterMarket":{"amount":206175.81,"volume":13997,"close":14.73,"buyVolume":0,"sellVolume":7621,"time":1789976037746,"indexStatus":"已收盘 09-21 15:30:00","preClose":12.7},"floatMarketCap":8428000000},"requestUrl":"/m/hq/s/688176/tweets","defaultTab":"tweets","newsList":[{"id":"2667568886","title":"每周股票复盘：亚虹医药（688176）将参加科创板业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667568886","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667568886?lang=zh_cn&edition=full","pubTime":"2026-09-13 04:02","pubTimestamp":1789243339,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，亚虹医药报收于12.44元，较上周的13.0元下跌4.31%。本周，亚虹医药9月8日盘中最高价报13.65元。本周关注点公司公告汇总：亚虹医药将于2026年9月16日参加科创板集体业绩说明会，就半年度经营成果与投资者交流。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300001567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","159938","BK1574","688176","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666581807","title":"亚虹医药（688176）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月9日股价下跌3.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666581807","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666581807?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:33","pubTimestamp":1788946428,"startTime":"0","endTime":"0","summary":"江苏亚虹医药科技股份有限公司近日发布《关于参加科创板2026年半年度创新药行业集体业绩说明会的公告》。公告显示，公司将于2026年9月16日15:00-17:00参加由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会，通过上证路演中心视频结合网络互动方式召开，会议将就公司2026年半年度经营成果、财务状况等与投资者进行交流。投资者可于2026年9月9日至9月15日16:00前通过上证路演中心网站或公司邮箱提交问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900029739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","09939","BK0239","BK1574","06978","BK1515","159938","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663937072","title":"亚虹医药（688176）披露2026年半年度报告，8月31日股价下跌0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663937072","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663937072?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:48","pubTimestamp":1788173298,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，亚虹医药报收于11.86元，较前一交易日下跌0.17%，最新总市值为67.86亿元。近日，江苏亚虹医药科技股份有限公司披露《2026年半年度报告》。本报告期实现营业收入155,353,308.79元，同比增长19.28%；利润总额为-244,770,829.97元；归属于上市公司股东的净利润为-238,604,759.91元；归属于上市公司股东的扣除非经常性损益的净利润为-250,930,825.16元。研发投入占营业收入的比例为127.67%，较上年同期增加38.23个百分点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100029627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1574","09939","BK1515","159938","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663481270","title":"亚虹医药（688176）2026年中报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2663481270","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663481270?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:15","pubTimestamp":1788041741,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亚虹医药发布2026年中报。根据财报显示，亚虹医药增收不增利。本次财报公布的各项数据指标表现一般。财报体检工具显示：建议关注公司现金流状况建议关注财务费用状况建议关注公司应收账款状况持有亚虹医药最多的基金为国联医疗健康混合A，目前规模为0.56亿元，最新净值1.2729，较上一交易日下跌1.3%，近一年上涨19.49%。本文数据来源于亚虹医药2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09939","688176","BK1574","BK1515","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663485130","title":"每周股票复盘：亚虹医药（688176）Q2收入增21.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663485130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663485130?lang=zh_cn&edition=full","pubTime":"2026-08-30 05:39","pubTimestamp":1788039551,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，亚虹医药报收于11.88元，较上周的12.2元下跌2.62%。本周，亚虹医药8月24日盘中最高价报12.3元。本周关注点来自业绩披露要点：2026年第二季度主营收入8426.74万元，同比上升21.89%。股本股东变化截至2026年6月30日，公司股东户数为2.4万户，较3月31日减少2289.0户，减幅为8.71%。公司发布2026年度“提质增效重回报”行动方案半年度评估报告，上半年实现营业收入15,535.33万元，同比增长19.28%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK1161","BK1515","BK0239","159938","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662062740","title":"亚虹医药（688176）披露APLD-2304获得欧盟CE认证，8月28日股价下跌0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662062740","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662062740?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:14","pubTimestamp":1787915646,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，亚虹医药报收于11.88元，较前一交易日下跌0.5%，最新总市值为67.98亿元。该股当日开盘12.08元，最高12.11元，最低11.83元，成交额达7847.04万元，换手率为1.15%。江苏亚虹医药科技股份有限公司于近日披露《自愿披露关于APLD-2304获得欧盟CE认证的公告》。公告显示，公司自主研发的APLD-2304产品近日获得欧盟CE认证及ISO 13485:2016体系认证。此次认证表明公司质量管理体系符合欧盟MDR法规要求，产品可在欧盟及认可该法规的地区销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800044701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","688176","BK1574","FSXEmain","09939","FESXmain","BK1515","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662011107","title":"亚虹医药：APLD-2304获欧盟CE认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2662011107","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662011107?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:27","pubTimestamp":1787830045,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659176955","title":"每周股票复盘：亚虹医药（688176）APL-2501获FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2659176955","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659176955?lang=zh_cn&edition=full","pubTime":"2026-08-16 03:10","pubTimestamp":1786821019,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，亚虹医药报收于12.98元，较上周的12.81元上涨1.33%。本周，亚虹医药8月13日盘中最高价报13.65元。本周关注点公司公告汇总：APL-2501获FDA同意开展晚期实体瘤临床试验公司公告汇总江苏亚虹医药科技股份有限公司控股子公司Baylink Biosciences Inc收到美国食品药品监督管理局函告，同意其自主研发的APL-2501开展用于治疗晚期实体瘤的临床试验。APL-2501是一种抗CLDN6/9抗体药物偶联物，拟用于多种晚期实体瘤治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0239","688176","09939","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659391163","title":"亚虹医药（688176）披露APL-2501临床试验申请获得FDA批准，8月13日股价上涨3.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659391163","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659391163?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:31","pubTimestamp":1786631471,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，亚虹医药报收于13.2元，较前一交易日上涨3.29%，最新总市值为75.53亿元。近日，江苏亚虹医药科技股份有限公司控股子公司Baylink Biosciences Inc收到美国食品药品监督管理局函告，同意其自主研发的APL-2501开展用于治疗晚期实体瘤的临床试验。APL-2501是一种抗CLDN6/9抗体药物偶联物，拟用于多种晚期实体瘤治疗。该临床试验申请获批对公司近期业绩无重大影响，药品研发仍存在技术、审批等不确定性风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688176","159938","BK1515","09939","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658200673","title":"每周股票复盘：亚虹医药（688176）就Photocure仲裁案提起反请求","url":"https://stock-news.laohu8.com/highlight/detail?id=2658200673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658200673?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:00","pubTimestamp":1786212048,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，亚虹医药报收于12.81元，较上周的11.36元上涨12.76%。本周，亚虹医药8月7日盘中最高价报12.87元。本周关注点公司公告汇总：亚虹医药及子公司就Photocure仲裁案提起反请求，要求返还660万美元及利息。此前，Photocure因合同纠纷于2026年7月提起仲裁，主张公司未支付全额里程碑款项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1515","159938","688176","09939","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657722528","title":"亚虹医药（688176）披露关于仲裁进展暨提起仲裁反请求的公告，8月5日股价上涨6.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657722528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657722528?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:12","pubTimestamp":1785939141,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，亚虹医药报收于12.4元，较前一交易日上涨6.8%，最新总市值为70.95亿元。该股当日开盘11.64元，最高12.49元，最低11.62元，成交额达2.29亿元，换手率为3.29%。近日，江苏亚虹医药科技股份有限公司发布《关于仲裁进展暨提起仲裁反请求的公告》。此前，Photocure因合同纠纷于2026年7月提起仲裁，主张公司未支付全额里程碑款项。公司表示已依约支付相关款项并保留权利，反请求已获受理，但尚未开庭审理，最终影响以仲裁结果为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1161","BK0239","09939","BK1574","688176","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052771","title":"每周股票复盘：亚虹医药（688176）收仲裁通知涉440万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052771","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654052771?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:58","pubTimestamp":1785002293,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，亚虹医药报收于12.58元，较上周的13.03元下跌3.45%。本周，亚虹医药7月22日盘中最高价报14.51元。Photocure请求裁定公司支付剩余440万美元及利息，并承担仲裁费用。目前仲裁已受理，尚未开庭。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK1574","09939","BK1161","BK1515","159938","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653295107","title":"亚虹医药（688176）披露关于收到仲裁通知的公告，7月23日股价上涨1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653295107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653295107?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:35","pubTimestamp":1784817317,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，亚虹医药报收于13.25元，较前一交易日上涨1.14%，最新总市值为75.82亿元。Photocure主张公司应支付因希维她获批而触发的1,100万美元里程碑款，公司已于2026年4月支付660万美元并保留权利，认为未触发全额付款义务。Photocure请求裁定公司支付剩余440万美元及利息，并承担仲裁费用。目前仲裁已受理，尚未开庭。该事项未对公司与Photocure的长期合作及正常经营造成实质性障碍，希维她的生产供应与商业化正有序推进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300048226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","BK1574","09939","BK1515","159938","688176"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648459390","title":"亚虹医药（688176）1.35亿股限售股将于7月1日解禁，占总股本23.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648459390","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648459390?lang=zh_cn&edition=full","pubTime":"2026-07-01 08:03","pubTimestamp":1782864190,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，亚虹医药于7月1日将有1.35亿股限售股份解禁，为公司追加承诺限售股份上市流通，占公司总股本23.68%。最近一年内，该股累计解禁5623.45万股，占总股本的9.83%。本文数据来源于亚虹医药公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100009448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","159938","688176","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646031302","title":"每周股票复盘：亚虹医药（688176）23.68%限售股将上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2646031302","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646031302?lang=zh_cn&edition=full","pubTime":"2026-06-28 02:57","pubTimestamp":1782586627,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，亚虹医药报收于9.19元，较上周的10.18元下跌9.72%。本周，亚虹医药6月23日盘中最高价报10.31元。6月26日盘中最低价报9.17元。亚虹医药当前最新总市值52.58亿元，在化学制药板块市值排名81/150，在两市A股市值排名3029/5206。涉及股东为PAN KE和ZHUANG CHENGFENG JOHN，分别持有129,465,348股和6,019,189股，解除限售后剩余限售股数量为0。上述股份锁定期为公司上市之日起三个完整会计年度后6个月，相关股东已严格履行限售承诺，保荐机构中信证券无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1161","BK0239","09939","BK1574","688176","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645832975","title":"亚虹医药（688176）披露首次公开发行部分限售股上市流通公告，6月23日股价上涨0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645832975","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645832975?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:22","pubTimestamp":1782224535,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，亚虹医药报收于10.04元，较前一交易日上涨0.5%，最新总市值为57.45亿元。近日，江苏亚虹医药科技股份有限公司发布首次公开发行部分限售股上市流通公告。公告显示，本次解除限售股份数量为135,484,537股，占公司当前总股本的23.68%。本次限售股将于2026年7月1日上市流通，涉及股东2名，分别为PAN KE和ZHUANG CHENGFENG JOHN；解除限售后剩余限售股数量为0。上述股东均严格履行了限售承诺，保荐机构中信证券对本次限售股上市流通无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09939","688176","BK1574","BK1515","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644632860","title":"每周股票复盘：亚虹医药（688176）两期股权激励完成归属","url":"https://stock-news.laohu8.com/highlight/detail?id=2644632860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644632860?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:19","pubTimestamp":1781893150,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，亚虹医药报收于10.18元，较上周的10.3元下跌1.17%。本周关注点公司公告汇总：2024年限制性股票激励计划首个归属期完成，归属2,551,416股。江苏亚虹医药科技股份有限公司完成2022年限制性股票激励计划首次授予部分第三个归属期及预留授予部分第二个归属期的股份登记工作。实际归属人数为73名，其中首次授予部分68人，归属923,932股；预留授予部分5人，归属97,750股。本次归属后公司总股本增至572,192,168股，未导致控股股东及实际控制人变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939","688176","BK1161","BK1515","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644742435","title":"亚虹医药（688176）披露核心技术人员调整公告，6月17日股价下跌2.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644742435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644742435?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:53","pubTimestamp":1781707990,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，亚虹医药报收于10.15元，较前一交易日下跌2.22%，最新总市值为58.08亿元。该股当日开盘10.3元，最高10.38元，最低10.1元，成交额达5654.03万元，换手率为1.27%。近日，江苏亚虹医药科技股份有限公司发布《关于调整核心技术人员的公告》。公告显示，公司新认定Ningshu Liu女士、马集先生为公司核心技术人员；原核心技术人员吴亮、孙龙伟不再认定为核心技术人员，但仍继续在公司任职。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700042515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643763494","title":"亚虹医药（688176）披露2024年限制性股票激励计划第一个归属期归属结果公告，6月16日股价上涨1.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643763494","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643763494?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:32","pubTimestamp":1781620335,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，亚虹医药报收于10.38元，较前一交易日上涨1.57%，最新总市值为59.29亿元。该股当日开盘10.22元，最高10.49元，最低10.07元，成交额达8857.87万元，换手率为1.98%。近日，江苏亚虹医药科技股份有限公司发布《关于2024年限制性股票激励计划第一个归属期归属结果公告》。公告显示，公司已完成2024年限制性股票激励计划第一个归属期的股份登记，本次归属股票数量为2,551,416股，来源为公司从二级市场回购的A股普通股股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600044284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639042306","title":"每周股票复盘：亚虹医药（688176）2025年股东会通过利润分配等议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2639042306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639042306?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:57","pubTimestamp":1780171028,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，亚虹医药报收于11.38元，较上周的12.39元下跌8.15%。北京市嘉源律师事务所对江苏亚虹医药科技股份有限公司2025年年度股东会的召集、召开程序、出席会议人员资格、召集人资格、表决程序及表决结果进行了见证，并出具法律意见书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789994350060,"stockEarnings":[{"period":"1week","weight":0.0209},{"period":"1month","weight":0.041},{"period":"3month","weight":0.2475},{"period":"6month","weight":-0.0716},{"period":"1year","weight":0.1411},{"period":"ytd","weight":0.1034}],"compareEarnings":[{"period":"1week","weight":0.0061},{"period":"1month","weight":0.0045},{"period":"3month","weight":-0.0437},{"period":"6month","weight":-0.0114},{"period":"1year","weight":0.0209},{"period":"ytd","weight":-0.0144}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏亚虹医药科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24001人(较上一季度减少8.71%)","perCapita":"23840股","listingDate":"2022-01-07","address":"江苏省泰州市海陵区药城大道一号(创业路东侧、园南路北侧)的新药创制基地二期D幢大楼1009房间","registeredCapital":"57219万元","survey":" 江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统肿瘤及女性健康领域，提供涵盖诊断、治疗、随访等诊疗一体化解决方案。公司的主要产品是APL-1702(希维她)、APL-2302、APL-2501、AT-021、APL-1706(海克威)、APLD-2304、APL-2401、APL-024、APL-1202、APL-1401、APL-2301。","listedPrice":22.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚虹医药-U(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚虹医药-U(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚虹医药-U,688176,亚虹医药-U股票,亚虹医药-U股票老虎,亚虹医药-U股票老虎国际,亚虹医药-U行情,亚虹医药-U股票行情,亚虹医药-U股价,亚虹医药-U股市,亚虹医药-U股票价格,亚虹医药-U股票交易,亚虹医药-U股票购买,亚虹医药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚虹医药-U(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚虹医药-U(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}